Loading...
XNAS
NVAX
Market cap1.12bUSD
Dec 05, Last price  
6.91USD
1D
0.73%
1Q
-12.53%
Jan 2017
-72.58%
Name

Novavax Inc

Chart & Performance

D1W1MN
XNAS:NVAX chart
P/E
—
P/S
1.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
44.57%
Rev. gr., 5y
105.39%
Revenues
682m
-30.65%
7,388,0004,683,0001,513,0001,064,000325,000343,00014,688,00022,076,00020,915,00030,659,00036,250,00015,353,00031,176,00034,288,00018,662,000475,598,0001,146,290,0001,598,951,000983,705,000682,162,000
Net income
-187m
L-65.60%
-11,174,000-23,068,000-34,765,000-36,049,000-38,374,000-35,708,000-19,364,000-28,507,000-51,983,000-82,947,000-156,937,000-279,966,000-183,769,000-184,748,000-130,102,000-427,505,000-1,743,751,000-657,939,000-545,062,000-187,499,000
CFO
-87m
L-87.78%
-5,809,000-14,810,000-26,742,000-24,310,000-32,830,000-32,852,000-23,629,000-18,229,000-45,359,000-67,014,000-126,090,000-255,467,000-138,696,000-184,825,000-136,623,000-42,541,000322,946,000-415,937,000-713,967,000-87,263,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
URL
https://www.novavax.com/
IPO date
May 16, 1973
Employees
1,992
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT